· Medicare is establishing the following limited coverage for CPT/HCPCS codes: 86141. Note: Use ICD-10-CM code Z74.09 and Z78.9 for patients at intermediate risk for CAD who do not have elevated lipids (i.e., do not meet criteria to use ICD-10-CM codes E78.00-E78.3 or E78.49). Group 1 Codes
· 2022 ICD-10-CM Diagnosis Code R79.82 2022 ICD-10-CM Diagnosis Code R79.82 Elevated C-reactive protein (CRP) 2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code R79.82 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
86141 C-REACTIVE PROTEIN; HIGH SENSITIVITY (HSCRP) ICD-10 Codes that Support Medical Necessity: It is the provider’s responsibility to select codes carried out to the highest level of specificity and selected from the ICD-10-CM code book appropriate to the year in which the service is rendered for the claim(s) submitted.
CPT codes: Code Description 86141 C-reactive protein; high sensitivity (hsCRP) The following ICD Diagnosis Codes are considered medically necessary when submitted with the CPT code above if medical necessity criteria are met: ICD-10 Diagnosis Codes ICD-10-CM-codes: Code Description E10.10 Type 1 diabetes mellitus with ketoacidosis without coma
ICD-10-CM Codes that Support Medical Necessity Note: Use ICD-10-CM code Z74. 09 and Z78. 9 for patients at intermediate risk for CAD who do not have elevated lipids (i.e., do not meet criteria to use ICD-10-CM codes E78. 00-E78.
High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation that predicts incident myocardial infarction, stroke, peripheral arterial disease, and sudden cardiac death among healthy individuals with no history of cardiovascular disease, and recurrent events and death in patients with acute or stable ...
Defining hs-CRP To illustrate the difference between CRP and hs-CRP, traditional testing measures CRP within the range of 10 to 1,000 mg/L, whereas hs-CRP values range from 0.5 to 10 mg/L. In simpler terms, hs-CRP measures trace amounts of CRP in the blood.
The hs-CRP test, or high-sensitivity CRP test, is a special CRP test that detects lower levels of CRP in the blood than the routine CRP lab test detects. The hs-CRP level is from 0.5–10 mg/L. Levels above 3 mg/L are considered high risk for developing cardiovascular disease.
Elevated C-reactive protein (CRP) 1 R79.82 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. 2 The 2021 edition of ICD-10-CM R79.82 became effective on October 1, 2020. 3 This is the American ICD-10-CM version of R79.82 - other international versions of ICD-10 R79.82 may differ.
The 2022 edition of ICD-10-CM R79.82 became effective on October 1, 2021.
C-reactive protein (CRP) is an acute phase reactant produced by the liver that has long been used to monitor inflammatory processes, such as infection and autoimmune diseases. Recent studies have suggested that low-level chronic inflammation may play a role in atherogenesis, and thus measurement of CRP has been investigated in various settings of cardiovascular disease, i.e., in patients with known cardiovascular disease, in patients with risk factors for cardiovascular disease, and as a general risk assessment tool for cardiovascular disease. To be used as a risk assessment tool, a greater precision at lower levels of CRP is needed such that the range of values collected in epidemiologic studies can be subdivided into quartiles and quintiles; in this way, the data from large epidemiologic studies can be applied to individual patients. Such technologies are collectively known as high sensitivity C-reactive protein (hsCRP).
Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.
The existing observational evidence establishes that CRP is an independent predictor of cardiovascular disease across a wide spectrum of patient populations. The evidence also suggests that using CRP as a component of a risk assessment tool will result in a more accurate cardiac risk prediction. While there is no scientific literature that directly tests the hypothesis that measurement of C-reactive protein to assess CHD risk results in improved patient outcomes, following discussion with local practitioners and a review of the existing literature, BCBSMA has determined that measurement of high sensitivity C-reactive protein (hsCRP) for assessment of coronary artery disease risk in the patients described in the policy statement is medically necessary.
CPT codes, descriptions and other data only are copyright 2021 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.
This LCD supplements but does not replace, modify or supersede existing Medicare applicable National Coverage Determinations (NCDs) or payment policy rules and regulations for hsCRP testing. Federal statute and subsequent Medicare regulations regarding provision and payment for medical services are lengthy. They are not repeated in this LCD.
Notice: It is not appropriate to bill Medicare for services that are not covered (as described by this entire LCD) as if they are covered.